Glaxo Wins U.S. FDA Approval for Wider Advair Use

The article states patients saw a 30% lower rate of worsening conditions than those being treated with salmeterol alone....BD

WASHINGTON (Reuters) May 01 - U.S. health regulators have said GlaxoSmithKline Plc's Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease (COPD), the drugmaker said on Wednesday.
The Food and Drug Administration's approval allows Glaxo to promote its product for COPD patients who experience flare-ups of the disease.
In a statement, Glaxo said the FDA also approved the use of Advair to include "not only patients with COPD associated with chronic bronchitis, but also emphysema or both conditions." Advair already is approved to prevent wheezing and to control other COPD symptoms